• Assay Search

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
      • New Drug Candidates
      • NDA/MAA-enabling Studies
      • Generic Drugs/Biosimilars
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • Phase I and ll Studies
      • Study Experience
      • In-hospital Beds
      • Cardiovascular Safety Services
      • Highly Automated ECG Core Lab
      • Metabolic Diseases
      • NAFLD/NASH
      • Belfast – Center of Excellence for Respiratory
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • AAHRPP Accreditation
      • Recruitment
    • Global Clinical Development
      • Vaccines
    • Data Management and Biometrics
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Clinical Data Sciences
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process – Internal Studies
      • Streamlined Data Flow Process – Multi-Site Studies
    • Global Bioanalytical Services
      • Assay Search
      • Small Molecule
      • Large Molecule
      • Biosimilars
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Global Clinical Development
      • Vaccines
    • Data Management and Biometrics
    • Global Bioanalytical Services
  • Celerion Asia
  • Tobacco Risk Evaluation
    • Protocol Development and Data Interpretation
    • Global Clinical Research
    • Global Bioanalytical Services
    • Global Regulatory Services
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Studies
    • Data Management and Biometrics
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Customized Program Planning for Opening IND Study
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • Celerion Video Library
  • News & Events
    • Blog
    • Press Room
    • Conferences/Events
    • Clinical Discussion Forums
      • Past Clinical Discussion Forums
  • Participate in a Study
  • Careers
  • Celerion Science Newsletter 2018 Q2
  • Celerion Science Newsletter 2018 Q1
  • Celerion Science Newsletter 2017 Q4
  • Celerion Science Newsletter 2017 Q3
  • Celerion Science Newsletter 2017 Q2
  • Celerion Science Newsletter 2017 Q1
  • Celerion Science Newsletter 2016 Q3

Generic Drugs/Biosimilars

Companies developing generic versions of marketed drugs utilize Celerion’s long-standing expertise and experience in the conduct of bioequivalence studies for market registration. Our scientists have successfully deployed adaptive and multiple treatment period designs to optimally manage bioequivalence studies of drugs with highly variable pharmacokinetic characteristics.

Celerion is an industry leader in the emerging area of biosimilar drug development by leveraging biologics regulatory expertise, proven large molecule and immunogenicity bioanalytical support, clinical study planning and execution and biopharmaceutics program development.

With a large network of clinical sites in Europe managing oncology and autoimmune drug studies, Celerion is well positioned to support the entire clinical development of biosimilar candidates. This includes managing clinical study conduct and supporting services such as immunogenicity assessment, bioanalysis, functional assays, data analysis and preparation of clinical study reports to regulatory standards.

Webinar: Biosimilar Development: Lessons Learned from Early Clinical Studies

Article: Bioanalytical Challenges of Biosimilars

Press Release: Celerion Appoints Dr. Marc Hoffman as Chief Medical Officer

Magazine: Global Bioanalytical Services

For more information contact us

  • LinkedIn
  • YouTube
  • Twitter

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2019 Celerion | Web Design by Aradius Group